



LUND
UNIVERSITY

The Latest Scientific Evidence on the Health Effects of Tropospheric Ozone, BC and PM_{2.5}

EBBA MALMQVIST THANKS TO ZORANA FOR SLIDES ON BC AND PM_{2.5}



Relative Risk (RR)

a	b
c	d

Relative risk is a ratio of an event:

persons exposed ■ persons unexposed

$\frac{\text{Incidence in the exposed}}{\text{Incidence in the non-exposed}}$

The larger the relative risk, the stronger the evidence for a causal relationship.

Large relative risk alone does not prove a causal relationship.


RR = 1: no evidence of an association

RR > 1: exposure is harmful

RR < 1: exposure may be protective



Pyramid of effects caused by air pollution



US EPA
2024



Causality steps



The five categories are:

- causal relationship;
- likely to be a causal relationship;
- suggestive of, but not sufficient to infer, a causal relationship;
- inadequate to infer the presence or absence of a causal relationship; and
- not likely to be a causal relationship.



(EMAPEC) WHO

Choices of morbidity outcomes and concentration–response functions for health risk assessment of long-term exposure to air pollution

Francesco Forastiere^{a,b,*}, Joseph V. Spadaro^{c,d}, Carla Ancona^e, Zorana Jovanovic Andersen^f, Ilaria Cozzi^e, Sophie Gumy^c, Dejan Loncar^c, Pierpaolo Mudu^g, Sylvia Medina^h, Roman Perez Velasco^g, Heather Walton^{b,i}, Jiawei Zhang^f, Michal Krzyzanowski^b

Table 2.

Relative risk estimates for incidence of diseases from selected systematic reviews recommended for health risk assessment of PM_{2.5} and NO₂

Outcome (incidence)	ICD-10 codes	Age (yrs)	List	RR (95% CI) per 10 µg/m ³	Mean exposure range (µg/m ³)	SR reference
Long-term exposure to PM _{2.5}						
Asthma in children	J45	0–18	A	1.34 (1.10, 1.63)	5–38	Khreis et al ³⁷
COPD	J41–J44	30+	A	1.18 (1.13, 1.23)	5–26	Park et al ³⁸
IHD events ^a	I21–I22	30+	A	1.13 (1.05, 1.22) ^b	5–65	Zhu et al ³⁹
Stroke	I60–I64	30+	A	1.16 (1.12, 1.20) ^b	5–36	Yuan et al ⁴⁰
Hypertension	I10–I11	30+	A	1.17 (1.05, 1.30) ^b	5–77	Qin et al ⁴¹
Diabetes (type 2)	E11–E14	30+	B+	1.10 (1.03, 1.18) ^b	5–79	Yang et al ⁴²
Dementia	F00–F03, G30	60+	B+	1.46 (1.20, 1.78) ^b	5–25 ^c	Cheng et al ⁴³
ASD	F84.0, F84.1, F84.5, F84.8, F84.9	2–12	B+	1.66 (1.23, 2.25) ^b	5–30 ^c	Lin et al ⁴⁴
Lung cancer	C34	30+	A	1.16 (1.10, 1.23)	5–44	Yu et al ³⁶
Long-term exposure to NO ₂						
Asthma in children	J45	0–18	A	1.10 (1.05, 1.18)	10–39	Khreis et al ³⁷
Asthma in adults	J45	19+	A	1.10 (1.01, 1.21)	10–40	HEI ³⁴
ALRI in children	J12–J18, J20–J22	0–12	A	1.09 (1.03, 1.16)	10–56	HEI ³⁴

^aAcute myocardial infarction (AMI).


^bRelative risk estimates from revised meta-analysis.

^cRestrict applicability of the CRFs of these conditions to exposure differences not larger than 10 µg/m³ within the indicated concentration ranges (see discussion in eAppendix 2; <http://links.lww.com/EE/A280>).



Mortality-PM_{2.5} 2024 meta-analyses WHO HRAPIE-2

- WHO HRAPIE-2 Project
- Orellano, 2024
- 53 studies
- RR = 1.095 (1.06-1.13)



Development of RRs mortality and long-term PM2.5 per 10 $\mu\text{g}/\text{m}^3$)

- HRAPIE (Hoek 2013) 1.062 (1.040-1.082)
- WHO 2021 AGQ (Chen&Hoek 2020) 1.080 (1.040-1.090)
- ELAPSE (Hoffmann 2022) 1.119 (1.060-1.179)
- HAPIE-2 (Orellano 2024) 1.095 (1.064-1.227)




Mortality: HRAPIE-2 Project WHO

- **PM_{2.5} RR = 1.095 (Orellano 2024)**
- **NO₂ RR= 1.045 (Kasdagli 2024)**
- **Sensitivity analyses European ELAPSE (Hoffmann, 2022) PM_{2.5} RR = 1.12 & NO₂ RR= 1.04**

Morbidity: EMAPEC Project WHO (Forastiere, 2024)

- **PM_{2.5} & NO₂**


What about ozone?



Meteorology



Ozone formation:
complex atmospheric chemistry



Transport



Hemispheric/
background O₃



Local O₃ levels regulated under
the EU's Ambient Air Quality Directive and
recommendations by WHO Air Quality Guidelines

+

Regional/local O₃



O₃


O₃

O₃

O₃

O₃

O₃ precursors emission: NMVOCs, CH₄ and NO_x




Anthropogenic sources:
agricultural, domestic,
traffic, industry...

Biogenic sources:
forests for NMVOCs
and wetlands for CH₄


Impacts on vegetation
(crops and forests)

Health impacts

Biological mechanisms



Ozone is highly reactive in the respiratory tract Devlin et al., (1997)



US EPA
2017

Ozone can cause the muscles in the airways to constrict, trapping air in the alveoli. This leads to wheezing and shortness of breath.

Table ES-1 Summary of causality determinations by exposure duration and health outcome.

Health Outcome ^a	Conclusions from 2013 Ozone ISA	Conclusions in the 2020 ISA
Short-term exposure to ozone		
Respiratory effects	Causal relationship	Causal relationship
Cardiovascular effects	Likely to be causal relationship	Suggestive of, but not sufficient to infer, a causal relationship ^d
Metabolic effects	No determination made	Likely to be causal relationship ^b
Total mortality	Likely to be causal relationship	Suggestive of, but not sufficient to infer, a causal relationship ^d
Central nervous system effects	Suggestive of a causal relationship ^d	Suggestive of, but not sufficient to infer, a causal relationship
Long-term exposure to ozone		
Respiratory effects	Likely to be causal relationship	Likely to be causal relationship
Cardiovascular effects	Suggestive of a causal relationship ^d	Suggestive of, but not sufficient to infer, a causal relationship
Metabolic effects	No determination made	Suggestive of, but not sufficient to infer, a causal relationship ^b
Total mortality	Suggestive of a causal relationship ^d	Suggestive of, but not sufficient to infer, a causal relationship
Reproductive effects	Suggestive of a causal relationship ^d	Effects on fertility and reproduction: suggestive of, but not sufficient to infer, a causal relationship ^b Effects on pregnancy and birth outcomes: suggestive of, but not sufficient to infer, a causal relationship ^b
Central nervous system effects	Suggestive of a causal relationship ^d	Suggestive of, but not sufficient to infer, a causal relationship
Cancer	Inadequate to infer a causal relationship	Inadequate to infer the presence or absence of a causal relationship ^d

^aHealth effects (e.g., respiratory effects, cardiovascular effects) include the spectrum of outcomes, from measurable subclinical effects (e.g., decrements in lung function, blood pressure) to observable effects (e.g., medication use, hospital admissions) and cause-specific mortality. Total mortality includes all-cause (nonaccidental) mortality, as well as cause-specific mortality.

^bDenotes new causality determination.

^cDenotes change in causality determination from 2013 Ozone ISA.

^dSince the 2013 Ozone ISA, the causality determination language has been updated and this category is now stated as suggestive of, but not sufficient to infer, a causal relationship.

^eSince the 2013 Ozone ISA, the causality determination language has been updated and this category is now stated as inadequate to infer the presence or absence of a causal relationship.




Figure ES-2 Causality determinations for health effects of short- and long-term exposure to ozone.

Proceedings for the Ozone Workshop US EPA 2024



Emerging research areas/findings include impact on the brain.



Increase in studies on COPD and other respiratory diseases.



In general, more linear concentration-response functions on short-term effects with no threshold.



Short-term effects of O₃ exposure, lag of one or two days for respiratory endpoints and had a lag of up to five days for cardiovascular endpoints.

Recent meta-analysis

Kasdagli et al.

Nitrogen Dioxide, Ozone and Mortality

TABLE 2 | Meta-analysis results and characteristics of studies informing the associations between long-term exposure to ozone (O₃) (per 10 µg/m³ increase) and mortality outcomes (Global, 2023-2024).

A) Annual O₃

	N	RR (95% CI)	I ² (%)	80% prediction interval	Sample size	Age (years)	Median of O ₃ (min – max)
All-cause	9	1.01 (0.96, 1.06)	92	(0.91, 1.11)	1,622,831	>30	60.6 (42.3–94.3)
Respiratory disease	6	1.05 (1.02, 1.08)	65	(1.00, 1.09)	1,544,274	>30	70.4 (50.8–94.3)
COPD	2	1.06 (1.03, 1.08)	25	-	1,217,826	>30	74.87–76.44*
ALRI	2	1.04 (0.97, 1.11)	80	-	1,217,826	>30	74.87–76.44*

B) Peak/warm season O₃

	N	RR (95% CI)	I ² (%)	80% Prediction Interval	Sample size	Age (years)	Median of O ₃ (min – max)
All-cause	12	1.01 (0.97, 1.04)	98	(0.92, 1.10)	107,896,036	>18	90.6 (74.9–106.6)
Respiratory disease	9	1.01 (0.98, 1.03)	92	(0.95, 1.06)	57,107,136	>25	85 (74.9–109.8)
COPD	7	1.00 (0.96, 1.04)	95	(0.92, 1.09)	56,668,296	>25	85 (74.9–109.8)
ALRI	4	1.02 (0.99, 1.04)	88	(0.97, 1.07)	23,702,383	>30	87.9 (74.9–109.8)

N = number of studies; min: minimum; max: maximum.

Kaudagli et al,
2024

What about BC?



2nd Global Conference on Air Pollution and Health

Overview of exposure and health effects of black carbon, evidence gaps

Session number: 7c

Bridging Air Pollution, Health and Climate: Tackling Black Carbon and Ultrafine Particles

March 26 / 14:30-16:00

*Zorana Jovanovic Andersen / Professor in Environmental Epidemiology, University of Copenhagen, Denmark;
Former Chair of ERS Environment and Health Committee*




Black Carbon (BC) and Co-pollutants from Incomplete Combustion

Black carbon particles are formed from the incomplete combustion of biomass and fossil fuels. It is a powerful climate forcer and dangerous air pollutant.

EMISSIONS

Main BC-rich sources by region and sector (2005)



PRIMARY BLACK CARBON-RICH SOURCES



BC is always emitted with co-pollutant particles, some of which have a cooling effect on climate. The ratio of BC to co-pollutants varies by source and determines if a measure has a **net warming** or **net cooling** effect.



IMPACTS


Suspended in the atmosphere, BC particles contribute to **global warming** by absorbing energy and converting it to heat

BC is a dangerous local air pollutant which can also be **transported across the globe**



Health Effects of Black Carbon. EPA (2019)

- **EPA Integrated Science Assessment for Particulate Matter (2019):** ‘PM Components and Sources: Many PM_{2.5} components and sources are associated with many health effects, and the evidence does not indicate that any one source or component is more strongly related with health effects than PM_{2.5} mass...’



Health Effects of Black Carbon: WHO Air Quality Guideline (2021)

Box 4.1. Good practice statement – BC/EC

Based on insufficient evidence to propose an AQG level, the GDG decided to formulate the following three good practice statements on BC/EC directed to countries and regional authorities.

1. Make systematic measurements of black carbon and/or elemental carbon. Such measurements should not replace or reduce the existing monitoring of pollutants for which guidelines currently exist.
2. Undertake the production of emission inventories, exposure assessments and source apportionment for BC/EC.
3. Take measures to reduce BC/EC emissions from within the relevant jurisdiction and, where considered appropriate, develop standards (or targets) for ambient BC/EC concentrations.

The image shows the cover of the WHO global air quality guidelines. It features a bright sun rising over a mountain range under a clear blue sky. The sun is positioned in the upper right quadrant, casting rays across the scene. The mountains are silhouetted against the sky. The text 'WHO global air quality guidelines' is prominently displayed in white, bold, sans-serif font in the lower right area. Below this, in a smaller font, are the pollutants covered: 'Particulate matter (PM_{2.5} and PM₁₀), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide'. The WHO logo and name are in the bottom right corner. The top right corner of the overall slide has a decorative grid of colorful squares in shades of blue, orange, purple, and green.

WHO global air quality guidelines

Particulate matter (PM_{2.5} and PM₁₀),
ozone, nitrogen dioxide, sulfur dioxide
and carbon monoxide




BC: review of epidemiological evidence: long-term exposure to BC and mortality

- Zhu X, et al. Short and long-term association of exposure to ambient black carbon with all-cause and cause-specific mortality: A systematic review and meta-analysis. *Environ Pollut.* **2023** May 1;324:121086.

RR is for an increase of 10 µg/m3 of BC

Study	Risk Ratio	RR	95%-CI	Weight
Mortality = Total				
Beelen.2008		1.050	[0.997; 1.106]	9.0%
Elliott.2007		0.900	[0.805; 1.006]	8.8%
Filleul.2005		1.070	[1.035; 1.106]	9.1%
Hansell.2016		1.020	[1.005; 1.035]	9.1%
Hoek.2002		1.530	[1.007; 2.324]	6.1%
Hvidfeldt.2019		2.367	[1.432; 3.914]	5.3%
Raaschou-Nielsen.2020		1.629	[1.224; 2.168]	7.4%
Yap.2012		1.100	[1.037; 1.167]	9.0%
Yap.2012		1.010	[0.961; 1.061]	9.1%
So.2022		2.183	[1.874; 2.542]	8.5%
Stafoggia.2022		1.844	[1.345; 2.529]	7.1%
Nilsson Sommar.2021		2.367	[1.035; 5.416]	3.1%
Bauwelinck.2022		1.051	[0.894; 1.236]	8.5%
Random effects model		1.298	[1.086; 1.550]	100.0%
Prediction interval			[0.650; 2.590]	--
Heterogeneity: $I^2 = 92%$, $\tau^2 = 0.0904$, $p < 0.01$				
Mortality = Cardiovascular disease				
Beelen.2009		1.110	[0.961; 1.282]	9.1%
Dehbi.2017		1.110	[0.763; 1.616]	6.9%
Elliott.2007		1.013	[1.012; 1.014]	9.6%
Hansell.2016		1.010	[0.980; 1.040]	9.6%
Hvidfeldt.2019		4.411	[1.704; 11.419]	2.7%
Raaschou-Nielsen.2020		0.737	[0.515; 1.056]	7.0%
Yang.2018		1.058	[1.021; 1.095]	9.6%
Yap.2012		1.110	[1.010; 1.220]	9.4%
Yap.2012		1.030	[0.949; 1.118]	9.5%
So.2022		1.605	[1.374; 1.874]	9.0%
Stafoggia.2022		1.416	[1.069; 1.878]	7.8%
Nilsson Sommar.2021		1.629	[0.475; 5.587]	1.8%
Bauwelinck.2022		0.668	[0.512; 0.873]	8.0%
Random effects model		1.093	[0.955; 1.250]	100.0%
Prediction interval			[0.670; 1.782]	--
Heterogeneity: $I^2 = 83%$, $\tau^2 = 0.0447$, $p < 0.01$				
Mortality = Ischemic heart disease				
Alexeef.2018		1.120	[0.942; 1.332]	12.3%
Beelen.2009		1.010	[0.833; 1.225]	12.1%
Gan.2011		1.642	[1.290; 2.089]	11.5%
Hansell.2016		1.020	[0.985; 1.056]	13.3%
Yang.2018		1.066	[1.010; 1.124]	13.3%
Yap.2012		1.130	[1.021; 1.251]	13.0%
Yap.2012		1.030	[0.944; 1.124]	13.1%
So.2022		1.605	[1.270; 2.028]	11.5%
Random effects model		1.149	[1.024; 1.291]	100.0%
Prediction interval			[0.775; 1.704]	--
Heterogeneity: $I^2 = 78%$, $\tau^2 = 0.0224$, $p < 0.01$				

Mortality = Coronary heart disease				
Alexeef.2018		1.120	[0.942; 1.332]	33.2%
Gan.2011		1.642	[1.290; 2.089]	30.9%
Hansell.2016		1.020	[0.985; 1.056]	35.9%
Random effects model		1.209	[0.921; 1.588]	100.0%
Prediction interval			[0.042; 34.972]	--
Heterogeneity: $I^2 = 87%$, $\tau^2 = 0.0508$, $p < 0.01$				
Mortality = Cerebrovascular disease				
Alexeef.2018		0.920	[0.582; 1.455]	26.3%
Beelen.2009		1.390	[0.993; 1.946]	31.9%
Yang.2018		1.041	[0.982; 1.104]	41.8%
Random effects model		1.082	[0.920; 1.273]	100.0%
Prediction interval			[0.220; 5.313]	--
Heterogeneity: $I^2 = 35%$, $\tau^2 = 0.0088$, $p = 0.22$				
Mortality = Respiratory disease				
Beelen.2008		1.220	[0.991; 1.502]	11.2%
Elliott.2007		1.300	[1.204; 1.404]	12.4%
Hansell.2016		1.050	[1.011; 1.091]	12.5%
Hvidfeldt.2019		1.000	[0.335; 2.984]	2.8%
Raaschou-Nielsen.2020		1.967	[1.122; 3.448]	6.6%
Yang.2018		0.992	[0.951; 1.034]	12.5%
Yap.2012		1.260	[1.022; 1.553]	11.2%
Yap.2012		0.970	[0.794; 1.185]	11.3%
So.2022		2.540	[2.028; 3.182]	11.0%
Bauwelinck.2022		1.766	[1.165; 2.675]	8.4%
Random effects model		1.319	[1.072; 1.623]	100.0%
Prediction interval			[0.637; 2.731]	--
Heterogeneity: $I^2 = 92%$, $\tau^2 = 0.0884$, $p < 0.01$				
Mortality = Lung cancer				
Beelen.2008		1.030	[0.882; 1.203]	11.4%
Elliott.2007		1.200	[0.930; 1.549]	10.2%
Filleul.2005		0.970	[0.931; 1.011]	12.1%
Hansell.2016		1.040	[0.991; 1.091]	12.1%
Raaschou-Nielsen.2020		1.967	[1.353; 2.859]	8.7%
Yap.2012		1.000	[0.837; 1.195]	11.1%
Yap.2012		1.110	[0.954; 1.292]	11.4%
So.2022		4.595	[3.435; 6.147]	9.8%
Stafoggia.2022		3.326	[1.836; 6.024]	6.0%
Nilsson Sommar.2021		0.122	[0.000; 1311.582]	0.0%
Bauwelinck.2022		2.602	[1.608; 4.211]	7.3%
Random effects model		1.540	[1.086; 2.185]	100.0%
Prediction interval			[0.422; 5.623]	--
Heterogeneity: $I^2 = 93%$, $\tau^2 = 0.2958$, $p < 0.01$				
Mortality = Chronic obstructive pulmonary disease				
Gan.2013		1.747	[1.018; 2.999]	21.6%
Hansell.2016		1.080	[1.022; 1.142]	39.4%
Yang.2018		0.983	[0.912; 1.060]	39.1%
Random effects model		1.051	[0.951; 1.162]	100.0%
Prediction interval			[0.366; 3.021]	--
Heterogeneity: $I^2 = 73%$, $\tau^2 = 0.0043$, $p = 0.03$				





BC: review of epidemiological evidence: long-term exposure to BC and mortality

New studies after meta analysis:

1. Zhu A, et al. Black Carbon Air Pollution and Incident Mortality Among the Advance-Aged Adults in China: A Prospective Cohort Study. *J Gerontol A Biol Sci Med Sci*. **2025**;80(4):glae302.
2. Weichenthal S, et al. Long-Term Exposure to Outdoor Ultrafine Particles and Black Carbon and Effects on Mortality in Montreal and Toronto, Canada. *Res Rep Health Eff Inst*. **2024**;2024:217.
3. Olstrup H, et al. The Long-Term Mortality Effects Associated with Exposure to Particles and NO_x in the Malmö Diet and Cancer Cohort. *Toxics*. **2023**;11(11):913.

Long-term exposure to black carbon and all-cause mortality: is effect of BC independent of that of PM_{2.5}?

Reference	Location	Study design / cohort name	Hazard ratio (95% CI) for BC	PM _{2.5} adjustment
Zhu et al. 2025	China (very old population)	Cohort study (CLHLS)	1.39 (1.36, 1.43), 1 µg/m ³	3.10 (2.94, 3.26)
Weichenthal et al. 2024	Montreal and Toronto, Canada	Cohort study (CanCHEC)	1.03 (1.03, 1.04), 0.5 µg/m ³	1.009 (1.004, 1.015) (PM _{2.5} and O _x)
Olstrup et al. 2023	Malmö, Sweden	Cohort study (MDC)	1.05 (1.02, 1.08), 0.15 µg/m ³	1.05 (1.02, 1.09)
So et al. 2022	Denmark	Cohort study (administrative)	1.05 (1.04, 1.06), 0.5 µg/m ³	1.03 (1.02, 1.04)
Stafoggia et al. 2022	European multi-countrywide	Cohort study (ELAPSE administrative cohorts)	1.04 (1.02, 1.06), 0.44 µg/m ³	1.03 (1.01, 1.05)
Bauwelinck et al. 2022	Belgium	Cohort study (administrative)	1.00 (1.00, 1.00), 0.44 µg/m ³	0.99 (0.99, 1.00)
			1.00 (1.00, 1.01), 0.44 µg/m ³	1.01 (1.00, 1.01)
Strak et al. 2021	European multi-cohort	Cohort study (ELAPSE pooled cohorts)	1.08 (1.06, 1.10), 0.44 µg/m ³	1.04 (1.02, 1.06)
Raschou-Nielsen et al. 2020	Denmark	Case-control (administrative cohort)	1.05 (1.02, 1.08), 1 µg/m ³	1.04 (1.01, 1.07)

BC and morbidity: long-term exposure to black carbon during pregnancy and maternal and fetal health

CHILD:

- Low birthweight (7 studies +, one-)
- Preterm birth (2 studies +, one-)
- Asthma incidence (one study +)
- Childhood wheeze (one study +)
- Hay fever and allergic rhinitis (one study +)
- Newborn systolic blood pressure (two studies +)
- Total fat mass, newborn insulin resistance (one study +)



MOTHER:

- Gestational diabetes mellitus (GDM) (one study +)
- Impaired glucose tolerance (IGT) (one study +)
- Preeclampsia (one study+)



Conclusion



- New ERFs for PM2.5 both mortality and morbidity
- Health effects also on long term exposure of ozone
- The evidence base on BC is increasing (new WHO report end of year)





THANKS FOR LISTENING!
ACKNOWLEDGING ALL THE PEOPLE BEHIND THE RESEARCH